$NSPR

Stuka Paul purchased $18K of NSPR

Stuka Paul purchased 20,000 shares of InspireMD, Inc. (NSPR) at $0.88 on 2026-05-27.

Original reporting
SEC EDGAR · Stuka Paul
Published May 29, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NSPR
Bullish
medium confidence
Mentioned
$NSPR
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NSPRBullishLow
01

Why it matters

The disclosed buy may slightly improve near-term sentiment, but without accompanying guidance, trial, regulatory, or financial updates, it is unlikely to materially re-rate the stock.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is not a standalone catalyst.

03

What to watch

No 10b5-1 plan is cited; however, the article does not clarify whether the director’s prior trading pattern suggests a signal or a one-off action.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed 2026-05-29 for a 2026-05-27 purchase

Background

The article is an SEC Form 4 insider transaction disclosure (director open-market purchase) for InspireMD, Inc.

Company-level read

Ticker impact

$NSPRBullishMedium confidence
Context

InspireMD director Stuka Paul bought 20,000 shares in an open-market transaction at $0.8750 on 2026-05-27, disclosed via Form 4.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than thesis-changing.

Evidence & confidence

The filing provides a discrete ownership change and price/size, but no new company-specific operational or financial information.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity/compensation-related or driven by diversification rather than a near-term outlook change.

Key entities

  • InspireMD, Inc.

    Company whose director insider purchase is disclosed on SEC Form 4.

  • Stuka Paul

    Director who purchased 20,000 shares of NSPR at $0.8750/share.

Related articles

$NSPRMedAI 8/10

InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures

InspireMD (Nasdaq: NSPR) reported 30-day results from its CGUARDIANS II trial of the CGuard Prime 80 cm implant for TCAR. In 50 high-risk patients, acute device success was 100% (50/50) with no deaths, strokes, MI, or stent thrombosis at 30 days. The company said an FDA PMA supplement is under review, with potential approval in H2 2026.